Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 6/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 3/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4071094 | 0.92 | STK17B (0.43) | IKBKBSTK17BKITFLT1MAP3K8 | |
| SCHEMBL4069670 | 0.92 | KIT (0.36) | IKBKBSTK17BKITFLT1MAP3K8 | |
| SCHEMBL4068418 | 0.90 | KIT (0.43) | IKBKBSTK17BKITFLT1MAP3K8 | |
| SCHEMBL3937343 | 0.90 | STK17B (0.44) | IKBKBSTK17BKIT | |
| SCHEMBL3933109 | 0.90 | STK17B (0.35) | IKBKBSTK17BKITFLT1MAP3K8 | |
| SCHEMBL3940275 | 0.90 | STK17B (0.40) | IKBKBSTK17BKITMAP3K8 | |
| SCHEMBL4069660 | 0.89 | IKBKB (0.41) | IKBKBSTK17BKITFLT1MAP3K8 | |
| SCHEMBL3933687 | 0.89 | STK17B (0.44) | IKBKBSTK17BKITFLT1MAP3K8 | |
| SCHEMBL4075080 | 0.88 | MAP3K8 (0.38) | IKBKBSTK17BKITFLT1MAP3K8 | |
| SCHEMBL4074733 | 0.88 | STK17B (0.35) | IKBKBSTK17BKITMAP3K8EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | IKBKB 2889/4885STK17B 1911/4885KIT 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.